Key Highlights
- RBC Capital Markets increased Astera Labs (ALAB) price target to $250 from $225, maintaining Outperform rating
- Scorpio-X switch revenue tied to Trainium3 deployments anticipated to begin in Q3 2026
- RBC forecasts Scorpio switch sales expanding from $130M in 2025 to $390M in 2026
- UBS initiated coverage with Neutral rating and $180 target, pointing to switching market competition
- Fourth quarter 2025 earnings per share of $0.58 exceeded analyst expectations of $0.51, with revenue climbing 92% YoY to $270.6M
Astera Labs experienced a notable Monday session, receiving attention from two separate Wall Street firms with contrasting perspectives on the semiconductor company’s prospects.
Astera Labs, Inc. Common Stock, ALAB
RBC Capital Markets elevated its price objective for Astera Labs to $250 from a previous $225, maintaining its Outperform stance. Shares were changing hands near $175.80 during the session, representing approximately 10% gains.
The optimistic outlook from RBC hinges on Scorpio-X, Astera’s upcoming advanced switch technology. Analysts anticipate revenue streams from Trainium3-connected Scorpio-X implementations to materialize starting in the third quarter of 2026, creating additional revenue potential per XPU deployed.
RBC forecasts aggregate Scorpio switch sales escalating from $130 million in 2025 to $390 million in 2026 — effectively tripling within a twelve-month period.
The revised $250 price objective applies a 74x multiple to RBC’s calendar 2027 earnings per share forecast of $3.37. The previous target utilized a 67x valuation multiple. RBC cited several new product launches, substantial total addressable market opportunity, anticipated revenue expansion of 40–50%, and gross profit margins exceeding 70% as rationale for the elevated multiple.
Astera’s current gross margin stands at 75.69%, accompanied by revenue growth of 115% across the trailing twelve months.
UBS Adopts a More Cautious Stance
UBS likewise commenced coverage on ALAB Monday, though established a Neutral position with a $180 price objective — marginally above the stock’s trading level.
Analyst Natalia Winkler recognized the company’s established presence in AI networking infrastructure over a five-year period, demonstrating solid execution with retimer products and diversifying customer relationships beyond its primary partner, AWS. Astera introduced its retimer offerings in 2019 and has subsequently expanded penetration across multiple hyperscale operators.
UBS anticipates 2027 revenues 4% higher than Wall Street consensus, propelled by retimers and the PCIe/UA Link switching product lineup. However, for 2028, UBS sits 3% beneath consensus expectations, highlighting intensifying switching market competition as a potential obstacle.
Valuation concerns represent the primary hesitation for UBS. Astera commands a high-40s 2027 price-to-earnings ratio, substantially elevated compared to AI networking sector peers. The firm indicated more attractive risk-reward opportunities exist elsewhere within the networking segment.
Strong Q4 Performance Supports Growth Narrative
Supporting both analytical perspectives is a robust recent quarterly report. Astera delivered Q4 2025 earnings per share of $0.58, surpassing the $0.51 Wall Street consensus by nearly 14%.
Quarterly revenue totaled $270.6 million, representing 92% year-over-year expansion.
Twelve analysts have increased earnings projections for the forthcoming period, based on InvestingPro data.
The stock has generated 223% returns over the trailing twelve months. Despite this substantial appreciation, ALAB’s PEG ratio of 0.47 indicates the valuation may remain reasonable relative to growth prospects — particularly when adjusting for the headline P/E of 143.
RBC’s $250 price objective suggests approximately 42% potential upside from present levels. UBS’s $180 target provides minimal upside opportunity from current trading ranges.


